467
edits
No edit summary |
No edit summary |
||
Line 1,020: | Line 1,020: | ||
===Prognosis=== | ===Prognosis=== | ||
[[Image:Image1.jpg|thumb|right|400px|Figure 9 Two-year mortality in landmark contemporary clinical heart failure trials (from Cleland et al)]] | |||
The life expectancy of a patient with heart failure is determined by age, NYHA class, LVEF, normal level of sodium, systolic blood pressure, use of medication and use of ICD or CRT-D (Seattle Heart failure score). The mean yearly annual mortality is about 10%, varying from <6% per year when a normal LVEF is found, to > 14% per year with an EF of < 15%. | The life expectancy of a patient with heart failure is determined by age, NYHA class, LVEF, normal level of sodium, systolic blood pressure, use of medication and use of ICD or CRT-D (Seattle Heart failure score). The mean yearly annual mortality is about 10%, varying from <6% per year when a normal LVEF is found, to > 14% per year with an EF of < 15%. | ||
Trials with medication illustrate that the (short term) benefit of medication is highest when the NYHA class is higher (Figure 9).<cite>11</cite> | Trials with medication illustrate that the (short term) benefit of medication is highest when the NYHA class is higher (Figure 9).<cite>11</cite> | ||
==References== | ==References== |
edits